Publication: Pediatrik nefroloji servisinde izlenen kronik böbrek hastalarında klinik eczacılık hizmetlerinin değerlendirilmesi
Abstract
Amaç: Bu araştırmanın amacı pediatrik nefroloji servisinde yatan hastalara klinik eczacılık hizmetleri sunulması, saptanan ilaç ilişkili sorunların (İLİS) sınıflandırılması ve klinik eczacının katkısının belirlenmesidir.Gereç ve Yöntem: Çalışma 1 Nisan-31 Ekim 2019 tarihleri arasında İnönü Üniversitesi Turgut Özal Tıp Merkezi Pediatrik Nefroloji Servisinde yürütülmüştür. Bu süreçte serviste yatan ve en az 1 ilaç kullanan 66 hasta çalışma grubuna dahil edilerek tedavilerindeki İLİS prospektif olarak değerlendirilmiş ve Avrupa Farmasötik Bakım Ağı (PCNE v.9) kullanılarak sınıflandırılmıştır. Çalışmanın başladığı tarihten geriye doğru yapılan taramada kayıtlarına ulaşılan ilk 66 hasta kontrol grubuna dahil edilmiş ve ilaç istemleri retrospektif olarak değerlendirilmiştir. Klinik eczacılık hizmetleri sunulan prospektif dönem ile kontrol grubunu oluşturan retrospektif dönem hastanede kalış süresi ve ilaç ilişkili sorunların dağılımı açısından karşılaştırılmıştır.Bulgular: 132 hastanın (66 kontrol, 66 çalışma) yaş medyan ve çeyrekler arası aralık (ÇAA) değerleri 60 ay (36-108), olarak hesaplanmıştır. Toplam 147 İLİS tespit edilmiş, bu sorunların büyük bir çoğunluğunun klinik eczacılık hizmetinin sunulduğu çalışma döneminde (134) saptandığı görülmüştür (p<0,001). En sık rastlanan İLİS nedenleri çalışma grubunda “hastayla ilgili” (%36,2), kontrol grubunda ise “doz seçimi” (%53,8) başlığına uygun kabul edilmiştir. Klinik eczacı tarafından yapılan önerilerinin %96,2’si kabul edilmiştir. Yatış süresi medyan değeri çalışma grubunda 7 (5-12,5) gün, kontrol grubunda ise 9,5 gün (7-13) olarak bulunmuştur (p<0,05). Sonuçlar: Bu çalışma, klinik eczacının pediatrik nefroloji servisinde yatan hastalarda İLİS saptanmasında ve çözümünde önemli bir rolü olduğunu ve klinik eczacılık hizmetlerinin yatış süresini kısaltmada potansiyel role sahip olduğunu göstermektedir.
Objective: The aim of this study is to provide clinical pharmacy services to hospitalized patients in the pediatric nephrology service, to classify the detected drug-related problems (DRPs) and to determine the clinical pharmacist's contribution.Methods: The study was conducted between April 1st and October 31st, 2019 at İnönü University Turgut Özal Medical Center Pediatric Nephrology service. In this process, 66 patients who were hospitalized in this service and using at least 1 drug were included in the study group and DRPs in their treatment protocol was prospectively evaluated according to the European Pharmaceutical Care Network (PCNE v.9). Patients were included in the control group, and their profiles were analyzed retrospectively using data obtained from medical reports for the first 66 patients collected immediately before April 1st. Both of the study group and control group were compared in terms of duration of hospital stay and distribution of DRPs.Results: The median age and interquartile range (IQR) values of the 132 patients (66 control group, 66 study group) were calculated as 60 months (36-108). A total of 147 DRPs were reported, with the majority (134) belonging to the study group where clinical pharmacy services were given (p<0,001). The most common causes of DRPs were “patient-related” (36,2%) in the study group, and “dose selection” (53,8%) in the control group. 96,2% of the clinical pharmacist’s interventions were accepted. The study group median duration of stay was 7 (5-12,5) days, while the control group was 9,5 days (7-13) days (p<0,05).Conclusion: This study demonstrates that clinical pharmacists play an important role in the diagnosis and resolution of DRPs in patients admitted to the pediatric nephrology service, and that clinical pharmacy services can help reduce length of stay.
Objective: The aim of this study is to provide clinical pharmacy services to hospitalized patients in the pediatric nephrology service, to classify the detected drug-related problems (DRPs) and to determine the clinical pharmacist's contribution.Methods: The study was conducted between April 1st and October 31st, 2019 at İnönü University Turgut Özal Medical Center Pediatric Nephrology service. In this process, 66 patients who were hospitalized in this service and using at least 1 drug were included in the study group and DRPs in their treatment protocol was prospectively evaluated according to the European Pharmaceutical Care Network (PCNE v.9). Patients were included in the control group, and their profiles were analyzed retrospectively using data obtained from medical reports for the first 66 patients collected immediately before April 1st. Both of the study group and control group were compared in terms of duration of hospital stay and distribution of DRPs.Results: The median age and interquartile range (IQR) values of the 132 patients (66 control group, 66 study group) were calculated as 60 months (36-108). A total of 147 DRPs were reported, with the majority (134) belonging to the study group where clinical pharmacy services were given (p<0,001). The most common causes of DRPs were “patient-related” (36,2%) in the study group, and “dose selection” (53,8%) in the control group. 96,2% of the clinical pharmacist’s interventions were accepted. The study group median duration of stay was 7 (5-12,5) days, while the control group was 9,5 days (7-13) days (p<0,05).Conclusion: This study demonstrates that clinical pharmacists play an important role in the diagnosis and resolution of DRPs in patients admitted to the pediatric nephrology service, and that clinical pharmacy services can help reduce length of stay.